Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results: A Hellenic Cooperative Oncology Group (HeCOG) study
Date
2005Author
Aravantinos, GerasimosFountzilas, George
Kosmidis, Paraskevas A.
Dimopoulos, M. A.
Stathopoulos, G. P.
Pavlidis, Nicholas
Bafaloukos, Dimitrios
Papadimitriou, C.
Karpathios, S.
Georgoulias, V.
Papakostas, P.
Kalofonos, H. P.
Grimani, E.
Skarlos, Dimosthenis V.
Source
Annals of OncologyVolume
16Issue
7Pages
1116-1122Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Background: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen combining alternating carboplatin and cisplatin plus paclitaxel. The two platinum derivatives have been previously combined as they are not totally cross-resistant and as they share no overlapping toxicities. Patients and methods: Patients with AOC, after the initial cytoreductive surgery were randomized to either 6 courses of paclitaxel at 175 mg/m2 as 3h infusion plus Carboplatin at 7 AUC (Arm A) or Paclitaxel at the same dose plus Carboplatin again at 7 AUC for cycles 1,3,5, while for cycles 2,4,6 Cisplatin at 75 mg/m2 substituted for Carboplatin (Arm B). Results: 247 patients are analyzed. Significant differences were not found, both in terms of PFS (38 vs 39 months, p=0.95) and overall survival (40.6 vs 38.6 months, p=0.79). There was not also difference in 5-year survival rate (35% vs 39%) or 5-year PFS rate (23% vs 28%). Age >60, PS 2, stage IV disease and presence of residual disease were adversely related to the overall survival. Conclusion: Both regimens are well tolerated and effective. Alternating cisplatin with carboplatin does not improve the results compared with the standard combination. © 2005 European Society fr Medical Oncology.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Prognosis of pregnancy-associated breast cancer: A meta-analysis of 30 studies
Jr, H. A. Azim; Santoro, L.; Russell-Edu, W.; Pentheroudakis, George; Pavlidis, Nicholas; Peccatori, Fedro A. (2012)Background: Pregnancy-associated breast cancer (PABC) is relatively rare with considerable controversy regarding its prognosis. Patients & methods: Two of the authors independently performed a literature search with no ...
-
Article
Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
Papaxoinis, G.; Papageorgiou, S.; Rontogianni, D.; Kaloutsi, V.; Fountzilas, George; Pavlidis, Nicholas; Dimopoulos, M. A.; Tsatalas, C.; Xiros, N.; Economopoulos, T. (2006)The aim of this retrospective study was to illustrate the clinicopathologic data and the treatment results in patients with primary gastrointestinal tract non-Hodgkin's lymphoma (GI NHL). Among 810 patients with NHL, 128 ...
-
Article
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: A study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial
Pliarchopoulou, K.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Eleftheraki, A. G.; Batistatou, Anna; Bobos, M.; Soupos, N.; Polychronidou, G.; Gogas, H.; Samantas, E.; Christodoulou, C.; Makatsoris, T.; Pavlidis, Nicholas; Pectasides, Dimitrios; Fountzilas, George (2013)Purpose: RACGAP1 is a Rac GTPase-activating protein involved in cell growth regulation, cell transformation and metastasis. The aim of the present study was to explore the prognostic and/or predictive significance of RACGAP1 ...